Business & FinanceBreaking NewsBreakingLatest News
Dr Reddy's Receives DCGI Approval for Esophageal Cancer Drug Zytorvi
Sentiment: NeutralHigh Priority
What Happened?
Dr Reddy's Laboratories has received approval from the DCGI for Zytorvi, an immunotherapy for advanced esophageal cancer. The drug is approved for use with cisplatin and paclitaxel.
Key points
- Zytorvi (toripalimab) is approved for first-line treatment of advanced esophageal squamous cell carcinoma.
- The drug is used in combination with cisplatin and paclitaxel.
- This is Zytorvi's second approved indication in India, expanding from nasopharyngeal carcinoma.
- Esophageal squamous cell carcinoma accounts for about 80% of esophageal cancer cases in India.
- The approval is based on results from the Phase 3 JUPITER-06 trial.
- In the trial, the combination therapy reduced the risk of disease or death by 42% compared to chemotherapy alone.
Key insights
- The approval may lead to increased accessibility of immunotherapy for cancer patients in India.
- Dr Reddy's expansion into new indications could strengthen its market position in oncology.
- The positive trial results may encourage further research and development in immunotherapy.
Why it matters
This approval could enhance treatment options for patients with advanced esophageal cancer in India.
Tags
Entities
Dr Reddy's Laboratories· CompanyZytorvi· ProductDCGI· OrganizationIndia· Country
Source
Business Standard
